Clarifications to Pediatric Drug Formulations
Walsh, K.
American Journal of Hospital Pharmacy 48(4): 682
1991
ISSN/ISBN: 0002-9289 PMID: 2042667 Document Number: 378673
Document emailed within 1 workday
Related Documents
Giacoia, G.P.; Taylor-Zapata, P.; Mattison, D. 2007: Need for appropriate formulations for children: the national institute of child health and human development-pediatric formulations initiative, part 2 International journal of pharmaceutical compounding 11(3): 220-221Torres Suárez, A.I. 2002: Polymers in ocular drug formulations Archivos de la Sociedad Espanola de Oftalmologia 77(2): 59-60
Fonseca, S. 2005: Basics of compounding for pediatric patients: commonly prescribed oral liquid formulations, vehicles, and stock solutions International Journal of Pharmaceutical Compounding 9(6): 456-461
Torkhovskaia, T.I.; Ipatova, O.M.; Medvedeva, N.V.; Ivanov, V.S.; Ivanova, L.I. 2010: Plasma lipoproteins as drug carriers. Effect of phospholipid formulations Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 5: 42-50
Schall, R.; Luus, H.G. 1992: Comparison of absorption rates in bioequivalence studies of immediate release drug formulations International Journal of Clinical Pharmacology Therapy and Toxicology 30(5): 153-159
Pannuti, F.; Strocchi, E.; Longhi, A.; Comparsi, R.; Camaggi, C.M. 1986: Medroxyprogesterone acetate plasma levels after a single oral administration of two drug formulations Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 5(4): 237-239
Margosis, M. 1971: Automated colorimetric determination of phenylephrine hydrochloride in drug formulations. II. Collaborative study Journal - Association of Official Analytical Chemists 54(3): 600-602
Schall, R.; Luus, H.G.; Steinijans, V.W.; Hauschke, D. 1994: Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations International Journal of Clinical Pharmacology and Therapeutics 32(7): 323-328
Schmidt, P.C.; Kaupp, H. 1993: Stability and new formulations of hexetidine. 2. Formulations and in vitro bioavailability Die Pharmazie 48(11): 837-841
Robinson, L.A. 1979: Pediatric drug information: drug therapy in nursing mothers Pediatric Nursing 5(6): 68-69; 84
Arayne, M.S.; Sultana, N.; Mirza, A.Z. 2006: Spectrophotometric method for quantitative determination of gliquidone in bulk drug, pharmaceutical formulations and human serum Pakistan Journal of Pharmaceutical Sciences 19(3): 185-189
Hansson, O. 1977: Welcome clarifications from CIBA-GEIGY Lakartidningen 74(37): 3095-3097
Bachman, A. 2009: TOSHA clarifications for physicians Tennessee Medicine: Journal of the Tennessee Medical Association 102(3): 31
Seth, B.L. 1992: Comparative pharmacokinetics and bioavailability study of percutaneous absorption of diclofenac from two topical formulations containing drug as a solution gel or as an emulsion gel Arzneimittel-Forschung 42(2): 120-122
Salehi-Isfahani, D 1987: On the Generalization of the Boserup Model: Some Clarifications Economic Development and Cultural Change 35(4): 875-881
Schurig, G. 2012: Clarifications regarding veterinary school accreditation Journal of the American Veterinary Medical Association 240(3): 260
Annunziato, L.; di Renzo, G. 1993: A bioequivalence study of tablet and powder formulations of the nonsteroidal anti-inflammatory drug 2-methoxyphenyl 1-methyl-5-(p-methylbenzoylpyrrol)-2-acetamidoacetate La Clinica Terapeutica 142(1 Part 2): 11-17
Vanprapar, N.; Cressey, T.R.; Chokephaibulkit, K.; Muresan, P.; Plipat, N.; Sirisanthana, V.; Prasitsuebsai, W.; Hongsiriwan, S.; Chotpitayasunondh, T.; Eksaengsri, A.; Toye, M.; Smith, M.E.; McIntosh, K.; Capparelli, E.; Yogev, R. 2010: A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand Pediatric Infectious Disease Journal 29(10): 940-944
Folco, G.; Borghi, C.; Berti, F. 1986: Non-steroidal antiinflammatory drug therapy: advantages and disadvantages of long half-life drugs versus slow-release formulations International Journal of Clinical Pharmacology Research 6(6): 475-480
Nykänen, P.; Sten, T.; Jürjenson, H.; Veski, P.; Marvola, M. 2004: Citric acid as a pH-regulating additive in granules and the tablet matrix in enteric-coated formulations for colon-specific drug delivery Die Pharmazie 59(4): 268-273